TL;DR
Researchers have identified PF-3845, a known inhibitor of human fatty acid amide hydrolase, as a potent new inhibitor of Mycobacterium tuberculosis phenylalanyl-tRNA synthetase (Mtb PheRS). This discovery offers a novel chemical scaffold for developing much-needed antibiotics against tuberculosis, with a unique bisubstrate inhibition mechanism and promising selectivity for the bacterial target over human counterparts.
What Problem Does This Paper Address?
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a major global health threat, exacerbated by the rise of drug-resistant strains. The development of new antibiotics is therefore a critical priority. Aminoacyl-tRNA synthetases (aaRSs), essential enzymes for protein synthesis, are attractive drug targets due to significant differences between bacterial and human versions, allowing for selective inhibition. Phenylalanyl-tRNA synthetase (PheRS) is one such target. While previous efforts have yielded some PheRS inhibitors, there's a continuous need for novel chemical scaffolds with distinct mechanisms of action to overcome resistance and improve therapeutic outcomes. This paper addresses this need by searching for new Mtb PheRS inhibitors with unique binding modes.
Methods
The study employed a multi-pronged approach:
- High-Throughput Screening (HTS): A library of 2148 bioactive compounds was screened against Mtb PheRS using a nonradioactive biochemical assay that couples pyrophosphate (PPi) production to a series of enzymatic reactions, ultimately generating a measurable signal.
- Enzyme Kinetics: Detailed kinetic studies were performed to characterize the inhibition mechanism of identified compounds, using Lineweaver-Burk plots to determine whether inhibition was competitive, noncompetitive, mixed, or uncompetitive with respect to the enzyme's substrates (phenylalanine, ATP, and tRNA).
- Protein Structural Modeling and Crystallography: The three-dimensional structures of Mtb PheRS, both in its apo form and in complex with inhibitors, were determined using X-ray crystallography. This allowed for visualization of the precise binding interactions and provided insights into the mechanism of inhibition and selectivity.
- Cellular Assays: The in vitro growth inhibition of Mtb strains was assessed using minimum inhibitory concentration (MIC) assays. An engineered strain with a tagged PheS subunit was used to confirm on-target activity within whole cells. Cytotoxicity assays were also performed on human cell lines to evaluate selectivity.
Datasets
The primary "dataset" in this study is the Selleck-2148 library, a collection of 2148 small molecules with known biological and pharmacological activities, used for the high-throughput screening. Additionally, the study utilized crystallographic data for Mtb PheRS (apo form, complexed with GD105-001, and complexed with PF-3845), which were deposited in the Protein Data Bank (accession codes 7DAW, 7DB7, and 7DB8).
Key Insights and Ideas
- Repurposing a Known Inhibitor: The identification of PF-3845, a compound previously known to inhibit human FAAH, as a potent Mtb PheRS inhibitor highlights the potential of repurposing existing drug scaffolds for new therapeutic targets.
- Novel Bisubstrate Inhibition: PF-3845 acts as a non-nucleoside bisubstrate competitive inhibitor, binding to both the phenylalanine (amino acid) pocket and the ATP pocket of Mtb PheRS. This dual binding mode is a significant departure from many existing inhibitors.
- The Crucial Role of Sulfate: A sulfate ion was found to be essential for PF-3845 binding, bridging interactions between the inhibitor and key residues in the ATP pocket. This suggests that the presence of sulfate in the cellular environment is critical for the inhibitor's efficacy.
- Structural Basis for Selectivity: Crystal structures revealed that PF-3845's binding mode is sterically incompatible with the active sites of human cytoplasmic and mitochondrial PheRS (hFARS1 and hFARS2), explaining its observed selectivity and lack of inhibition against these human counterparts. Differences in the size and conformation of the amino acid pocket are key.
- A New Chemical Scaffold: PF-3845 represents a distinct chemical scaffold compared to previously identified PheRS inhibitors, offering a new avenue for medicinal chemistry optimization.
Key Results
- PF-3845 was identified as an Mtb PheRS inhibitor with a K<sub>i</sub> of approximately 0.73 µM.
- The compound inhibited the in vitro growth of Mtb H37Rv at a minimum inhibitory concentration (MIC) of ~24 µM.
- Potency increased against an engineered Mtb strain (pheS-FDAS), indicating on-target activity in whole cells.
- PF-3845 demonstrated selectivity, showing no inhibition of human cytoplasmic or mitochondrial PheRS at concentrations up to 200 µM.
- Kinetic analysis revealed PF-3845 to be a competitive inhibitor with respect to phenylalanine, a mixed inhibitor with respect to ATP, and an uncompetitive inhibitor with respect to tRNA. In the presence of sulfate, it became a competitive inhibitor with respect to ATP.
- The 2.3-Å crystal structure of Mtb PheRS in complex with PF-3845 elucidated its novel binding mode, occupying both the amino acid and ATP pockets, with a sulfate ion playing a critical role in stabilizing interactions.
Limitations and Future Work
- Cytotoxicity: While PF-3845 shows selectivity for Mtb PheRS, its cytotoxicity against human cancer cell lines (CC<sub>50</sub> around 16.9-21.7 µM) is a concern. This suggests that further medicinal chemistry efforts are needed to optimize the scaffold for improved therapeutic index, potentially by modifying the piperidine-piperazine urea moiety.
- Drug-likeness: PF-3845's molecular weight and cLogP are at the upper limit of Pfizer's rule of five, indicating potential challenges with oral bioavailability.
- Unidentified Cellular Targets: The study notes that PF-3845 might inhibit other cellular proteins in human cells, contributing to its observed cytotoxicity. Identifying these targets is a crucial next step.
- Future Directions: The authors propose further medicinal chemistry efforts to optimize PF-3845 for potency, reduced toxicity, and development as a clinical TB drug candidate. They also suggest exploring its potential as an anti-Gram-negative lead and using it as a chemical probe to study bacterial and human PheRS function and evolution. The robust assays developed in this study will be valuable for future drug discovery efforts.
Summary updated